• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

World First As UK Greenlights Landmark CRISPR Gene Editing Treatment

November 17, 2023 by Deborah Bloomfield

The world’s first CRISPR-based therapy has been approved by the UK medicines regulator, it was announced on Thursday. The pioneering treatment, which involves the much-lauded gene-editing method CRISPR, will target two blood conditions: sickle-cell disease and beta-thalassemia.

“This is a landmark approval which opens the door for further applications of CRISPR therapies in the future for the potential cure of many genetic diseases,” Kay Davies, a professor of anatomy at the University of Oxford, told the Science Media Centre.

Advertisement

According to an announcement from the medicine’s manufacturers, Vertex Pharmaceuticals and CRISPR Therapeutics, the treatment, called CASGEVY, has been authorized for certain sickle-cell disease or beta thalassemia patients aged 12 and up – around 2,000 people in the UK will be eligible to receive it.

It is thought that the US will soon follow suit, with the Food and Drug Administration expected to approve the therapy for sickle-cell patients in December and for beta-thalassemia patients next March.

Casgevy is based on the CRISPR-Cas9 gene editing system that revolutionized the field of genome engineering when its discovery was announced back in 2012. Since then, it’s been used in all manner of research, in our species and others, winning its developers a Nobel Prize in 2020.

“I am excited and a bit overwhelmed with emotion at the news of the approval of CASGEVY in the UK. Going from the lab to an approved CRISPR therapy in just 11 years is a truly remarkable achievement,” one of the system’s developers, Jennifer Doudna, said of the latest breakthrough.

Advertisement

“I am especially pleased that the first CRISPR therapy helps patients with sickle cell disease, a disease that has long been neglected by the medical establishment. This is a win for medicine and for health equity.”

Sickle-cell disease and beta-thalassemia are caused by errors in genes that code for hemoglobin – the protein in red blood cells that delivers oxygen to our tissues. 

CASGEVY makes use of the CRISPR-Cas9 system to edit a gene called BCL11A, which normally prevents production of a type of fetal hemoglobin. In doing so, it disrupts that gene, meaning the hemoglobin, which is free of the abnormalities associated with sickle-cell disease and beta-thalassemia, can be produced.

When gene-edited cells are then infused back into patients, they mature into red blood cells that contain fetal hemoglobin, and therefore boost oxygen supply to the tissues and alleviate patients’ symptoms.

Advertisement

The treatment’s approval comes off the back of promising clinical trial results, which identified no serious safety issues. However, some experts have raised potential concerns.

“It is well known that CRISPR can result in spurious genetic modifications with unknown consequences to the treated cells,” Professor David Rueda of Imperial College London told the Science Media Centre. “It would be essential to see the whole-genome sequencing data for these cells before coming to a conclusion. Nonetheless, this announcement makes me feel cautiously optimistic.”

It’s also likely to cost a lot – a price has not yet been set in the UK – which, unfortunately, will limit its reach.

“The challenge is that these therapies will be very expensive so a way of making these more accessible globally is key,” Davies added.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Soccer – FIFA backs down on threat to fine Premier clubs who play South American players
  2. U.S. House passes abortion rights bill, outlook poor in Senate
  3. Two children killed in missile strikes on Yemen’s Marib – state news agency
  4. We’ve Breached Six Of The Nine “Planetary Boundaries” For Sustaining Human Civilization

Source Link: World First As UK Greenlights Landmark CRISPR Gene Editing Treatment

Filed Under: News

Primary Sidebar

  • Orcas Filmed Kissing (With Tongues) In The Wild For The First Time
  • How Easy Is It For A Country To Change Its Time Zone?
  • Earth’s First Commercial Space Station Set To Launch In 2026
  • Black Hole Moon: Rogue Planets With Weird Signatures Could Be A Sign Of Advanced Alien Life
  • World’s Largest Ephemeral Lake Set To Turn Iconic Peachy Pink After Extreme Flooding
  • Stunning New JWST Observations Give Further Evidence That Dark Matter Is A Real Substance
  • How Big Is This Spider? Study Explains Why You Might Overestimate Their Size
  • Orcas Sometimes Give Humans Presents Of Food And We Don’t Know Why
  • New Approach For Interstellar Navigation Was Tested On A Spacecraft 9 Billion Kilometers Away
  • For Only The Second Recorded Time, Two Novae Are Visible With The Naked Eye At Once
  • Long-Lost Ancient Egyptian City Ruled By Cobra Goddess Discovered In Nile Delta
  • Much Maligned Norwegian Lemming Is One Of The Newest Mammal Species On Earth
  • Where Are The Real Geographical Centers Of All The Continents?
  • New Species Of South African Rain Frog Discovered, And It’s Absolutely Fuming About It
  • Love Cheese But Hate Nightmares? Bad News, It Looks Like The Two Really Are Related
  • Project Hail Mary Trailer First Look: What Would Happen If The Sun Got Darker?
  • Newly Discovered Cell Structure Might Hold Key To Understanding Devastating Genetic Disorders
  • What Is Kakeya’s Needle Problem, And Why Do We Want To Solve It?
  • “I Wasn’t Prepared For The Sheer Number Of Them”: Cave Of Mummified Never-Before-Seen Eyeless Invertebrates Amazes Scientists
  • Asteroid Day At 10: How The World Is More Prepared Than Ever To Face Celestial Threats
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version